• Worst Pills, Best Pills



• Health Letter



• Health Links



• Activist Courses



• Take Action!



• Drug Safety



• Healthcare Delivery



• Medical Devices



• Food Safety



• Occupational Health

Publications:

» (6/29/09) Public Citizen's Response to FDA Draft Guidance on Conduct of Clinical Trials in Community-Acquired Bacterial Pneumonia (HRG Publication #1886) » (6/24/09) Testimony of Peter Lurie, M.D., M.P.H and Hillary Peabody, M.P.H before the FDA Transparency Task Force (HRG Publication #1883) » (2/27/08) Testimony before the Congressional Agriculture-FDA Appropriations Subcommittee hearing on drug safety (HRG Publication #1835) » (12/28/07) Comments on FDA's Draft Guidance for Industry - Drug-Induced Liver Injury: Premarketing Clinical Evaluation (HRG Publication #1833) » (12/26/07) Comments on the Draft Report on the U.S. System of Oversight of Genetic Testing (HRG Publication #1832) » (11/14/07) Testimony of Sidney M. Wolfe M.D. on Behind-the-Counter Availability of Certain Drugs (HRG Publication #1828) » (10/9/07) Letter to the FDA urging action against a campaign promoting the unapproved use of Topamax for treating alcoholics (HRG Publication #1825) » (7/16/07) Letter urging that rimonabant and etoricoxib be removed from the European market (HRG Publication #1818) » (6/21/07) Petition to Require That Certain Advisory Committee Meetings Include an FDA Staff Presentation (HRG Publication #1816) » (5/22/07) Testimony on Programs Affecting Safety and Innovation in Pediatric Therapies (HRG Publication #1811) » (5/4/07) Letter to Congress Regarding Prescription Drug User Fee Act (PDUFA) (HRG Publication #1810) » (3/19/07) Comments to the FDA: Access to and Charging for Investigational Drugs (HRG Publication #1800) » (1/3/07) Letter in the Lancet: Suboptimum use of FDA drug advisory committees (HRG Publication #1796) » (10/10/06) Article in Law and Contemporary Problems: Access to Pharmaceutical Data at the FDA (HRG Publication #1789) » (8/24/06) The US FDA at a Crossroads (HRG Publication #1780) » (4/28/06) Comments to the New Zealand Ministry of Health on Direct-to-Consumer Advertising of Prescription Drugs (HRG Publication #1767) » (4/25/06) Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings (HRG Publication #1765) » (4/3/06) Comments to the FDA on good manufacturing practices for Phase I clinical drug trials (HRG Publication #1763) » (1/19/06) Statement Before the Institute of Medicine Committee Assessing the U.S. Drug Safety System (HRG Publication #1759) » (12/7/05) Statement by Sidney Wolfe, MD, at the Public Hearing on CDER's Current Risk Communication Strategies for Human Drugs (HRG Publication 1758) >> more publications...

more resources

Because Public Citizen does not accept funds from corporations, professional associations or government agencies, we can remain independent and follow the truth wherever it may lead. But that means we depend on the generosity of concerned citizens like you for the resources to fight on behalf of the public interest. If you would like to help us in our fight, click here.